EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte Studie

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

Sara M Tolaney, Zefei Jiang, Qingyuan Zhang, Romualdo Barroso-Sousa, Yeon Hee Park, Mothaffar F Rimawi, Cristina Saura, Andreas Schneeweiss, Masakazu Toi, Yee Soo Chae, Yasemin Kemal, Mukesh Chaudhari und 9 weitere

New England Journal of Medicine · 05.02.2026 · 394 (6) · 551-562

DOI: 10.1056/nejmoa2508668 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 05.02.2026. Verfasst von Sara M Tolaney und 20 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Daiichi Sankyo Company, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabAdultAgedFemaleHumansMiddle AgedCamptothecinDouble-Blind MethodIntention to Treat AnalysisNeoplasm MetastasisProgression-Free SurvivalTaxoidsBridged-Ring CompoundsYoung AdultAged, 80 and over

Substanzen

Antibodies, Monoclonal, HumanizedCamptothecinErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanImmunoconjugatespertuzumabtaxaneTaxoidsTrastuzumabtrastuzumab deruxtecan

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Harvard Medical School, Boston.
  • Department of Breast Cancer, Fifth Medical Center of People's Liberation Army General Hospital, Beijing.
  • Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Brasilia Hospital, Rede Américas, Brasilia, Brazil.
  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston.

Förderung

  • Daiichi Sankyo Company
  • AstraZeneca

Zitieren

APA

Tolaney, S. M., Jiang, Z., Zhang, Q., Barroso-Sousa, R., Park, Y. H., Rimawi, M. F., Saura, C., Schneeweiss, A., Toi, M., Chae, Y. S., Kemal, Y., Chaudhari, M., Şendur, M. A. N., Yamashita, T., Casalnuovo, M., Danso, M. A., Liu, J., Shetty, J., Herbolsheimer, P., …, & DESTINY-Breast09 Trial Investigators (2026). Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 394(6), 551-562. https://doi.org/10.1056/nejmoa2508668

Vancouver

Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, et al. Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine. 2026;394(6):551-562. doi:10.1056/nejmoa2508668

BibTeX
@article{Tolaney2026,
  author = {Tolaney, Sara M and Jiang, Zefei and Zhang, Qingyuan and Barroso-Sousa, Romualdo and Park, Yeon Hee and Rimawi, Mothaffar F and Saura, Cristina and Schneeweiss, Andreas and Toi, Masakazu and Chae, Yee Soo and Kemal, Yasemin and Chaudhari, Mukesh and Şendur, Mehmet A N and Yamashita, Toshinari and Casalnuovo, Monica and Danso, Michael A and Liu, Jie and Shetty, Jagdish and Herbolsheimer, Pia and Loibl, Sibylle and DESTINY-Breast09 Trial Investigators, DESTINY-Breast09 Trial Investigators},
  title = {Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {6},
  pages = {551--562},
  doi = {10.1056/nejmoa2508668}
}
Kostenlos starten →